Oleoylethanolamide (OEA)

Synonimy: Oleoylethanolamide, OEA, N-Oleoylethanolamine, Oleic acid monoethanolamide, N-(2-Hydroxyethyl)oleamide, (9Z)-N-(2-Hydroxyethyl)-9-octadecenamide, Oleamide MEA

Oleoylethanolamide (OEA) is a naturally occurring lipid mediator belonging to the class of N-acylethanolamines (NAEs), which also includes the better-known endocannabinoid anandamide and the satiety factor palmitoylethanolamide (PEA). It is biosynthesized in the small intestine and other tissues from oleic acid and phosphatidylethanolamine, and its levels are regulated by the enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) and degraded primarily by fatty acid amide hydrolase (FAAH). While OEA was first identified in the 1960s, it gained significant attention in the 2000s when it was recognized as a key endogenous signal in the regulation of feeding behavior and lipid metabolism.

From a chemical standpoint, OEA is a monounsaturated fatty acid ethanolamide with a cis double bond at the 9-position of the C18 acyl chain. This structural feature distinguishes it from its saturated analog palmitoylethanolamide (PEA; C16:0) and from the polyunsaturated anandamide (AEA; C20:4). The presence of the oleoyl moiety confers unique physicochemical properties, including a lower melting point and distinct receptor binding profile. OEA exerts its biological effects primarily through activation of the nuclear receptor PPAR-alpha (peroxisome proliferator-activated receptor alpha), which mediates many of its metabolic actions, though additional targets such as GPR119 and TRPV1 have been implicated in specific contexts.

In the dietary supplement and pharmaceutical research sectors, OEA is valued for its role in satiety signaling, fat oxidation, and energy homeostasis. It is frequently formulated alongside other lipid mediators or used as a reference standard in analytical laboratories. The compound is also investigated for its neuroprotective and anti-inflammatory potential, although its primary commercial demand stems from weight management and metabolic health applications. As a bulk raw material, OEA is typically produced via synthetic routes or enzymatic synthesis to ensure high purity and consistent quality, meeting the rigorous demands of nutraceutical and clinical research customers.

Funkcja

• Satiety regulation: Activates PPAR-alpha in the small intestine, triggering neural signals that reduce food intake and meal size.
• Lipid metabolism: Enhances fatty acid oxidation and lipolysis in adipose tissue and liver, supporting energy expenditure.
• Anti-inflammatory activity: Modulates cytokine production and reduces macrophage activation in metabolic tissues.
• Ochrona neuronów: Exhibits protective effects in models of neurodegeneration, potentially via PPAR-alpha-dependent pathways.
• Gut-brain axis signaling: Influences vagal afferent activity, linking intestinal lipid sensing to central appetite control.

Source & Standardization

• Źródło: Synthetic or enzymatic synthesis from oleic acid and ethanolamine.
• Production: Amidation reaction followed by purification via crystallization or chromatography.
• Standardization: ≥98.0% by HPLC (area normalization).
• Forms: White to off-white crystalline powder or waxy solid.
• Zastosowania: Dietary supplements, functional foods, pharmaceutical research, analytical standards.

Dane techniczne

Documentation & Supply

• Miesięczna wydajność: 500 kg
• Czas realizacji: 3–5 dni roboczych (towary dostępne w magazynie)
• Dokumentacja: COA, MSDS, TDS, and additional technical support available upon request
• Opakowanie: 1 kg, 5 kg, 25 kg net weight in fiber drums with double polyethylene liners, or as customized

Zapytanie ofertowe

• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com